GSK seeks bids for $4bn India sale by mid-Sept

UK pharmaceutical giant GSK has requested bids by mid-September for its $4.3-billion Indian consumer-health unit, which owns the popular malted milk brand Horlicks, people with knowledge of the matter said.

GSK has sent out an information memorandum with preliminary details about the business to potential suitors, according to the people, who asked not to be identified because the information is private. The sale has attracted interest from potential bidders including Nestle, PepsiCo and Reckitt Benckiser Group, they said.

The UK drugmaker announced in March that it aims to complete a strategic review of Horlicks and other nutritional products by the end of this year. The company is assessing its 72.5% holding in India-listed GSK Consumer Healthcare as part of that process. Proceeds from a potential sale could be used to finance GSK’s $13-billion buyout of Novartis’ stake in their consumer-health joint venture. Representatives for Glaxo and Nestle declined to comment. Spokesmen for Reckitt and Pepsi had no immediate comment.

GSK’s review of assets includes its 82% stake in the Dhaka-listed GSK Bangladesh, as well as marketing rights to some consumer-health brands in other emerging economies, the people said. There’s no certainty the deliberations will lead to a transaction, and the parent company may yet decide to keep the businesses, they said. Shares of GSK Consumer Healthcare have advanced almost 10% in Mumbai trading this year, giving it a market value of Rs 29,900 crore ($4.3 billion).

  • Related Posts

    Gaudium IVF launches AI powered Signature Labs; kicks off 19 centre expansion

    Gaudium IVF and Women Health Limited, India’s first publicly listed IVF chain, kicked off its first milestone in the company’s planned 19-centre expansion, as outlined in the growth roadmap shared…

    WHO releases updated guidelines on reducing the risk of cognitive decline and dementia

    The World Health Organization (WHO) released updated guidelines on reducing the risk of cognitive decline and dementia, providing countries with evidence-based recommendations to help prevent or delay the onset of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Gaudium IVF launches AI powered Signature Labs; kicks off 19 centre expansion

    Gaudium IVF launches AI powered Signature Labs; kicks off 19 centre expansion

    WHO releases updated guidelines on reducing the risk of cognitive decline and dementia

    WHO releases updated guidelines on reducing the risk of cognitive decline and dementia

    Kerala researchers develop biosensor to measure snake venom for faster treatment

    Kerala researchers develop biosensor to measure snake venom for faster treatment

    Hyderabad pharma firm executives donate ₹2 crore to TTD scheme in Tirumala

    Hyderabad pharma firm executives donate ₹2 crore to TTD scheme in Tirumala

    Pharma pricing policy threatens innovation

    Pharma pricing policy threatens innovation

    16 empanelled hospitals face action after negligence in Ayushman Scheme

    16 empanelled hospitals face action after negligence in Ayushman Scheme